What is EnteroBiotix?
EnteroBiotix is a clinical-stage biopharmaceutical enterprise dedicated to pioneering full-spectrum microbiome therapeutics. The company is currently focused on the advancement of its lead product, EBX-102-02, which is positioned as a potential disease-modifying therapy for irritable bowel syndrome. Following promising results from the TrIuMPH Phase 2a trial, the organization is now scaling its operations to support the Phase 2b RISE trial. By targeting the complex interactions within the human microbiome, EnteroBiotix aims to redefine treatment paradigms for gastrointestinal disorders, moving beyond symptomatic relief toward curative interventions.
How much funding has EnteroBiotix raised?
EnteroBiotix has raised a total of $91.6M across 7 funding rounds:
Angel/Seed
$4M
Series A
$21.5M
Debt
$14.6M
Private Equity
$19.8M
Stock/Share Issuance
$1.4M
Stock/Share Issuance
$5.3M
Unspecified
$25M
Angel/Seed (2019): $4M with participation from Syndicate Room, Scottish Enterprise, Barwell, Fund Twenty8, SIS Ventures, NCIMB, Gabriel, University of Aberdeen, Bank Workers Charity, and Equity Gap
Series A (2021): $21.5M led by Kineticos Ventures, Scottish Enterprise, Thairm Bio, and SIS Ventures
Private Equity (2024): $19.8M supported by Kineticos
Debt (2024): $14.6M featuring Scottish National Investment Bank
Stock/Share Issuance (2025): $1.4M, investors not publicly disclosed
Stock/Share Issuance (2026): $5.3M, investors not publicly disclosed
Unspecified (2026): $25M led by Scottish National Investment Bank
Key Investors in EnteroBiotix
Scottish National Investment Bank
The Scottish National Investment Bank is a development investment bank established to provide long-term, patient capital investments for businesses, projects, and communities across Scotland.
Kineticos
Founded in 2007, Kineticos is a specialized management consulting firm serving the life science industry, focused on corporate strategy, operational execution, and innovation services.
Scottish Enterprise
Scottish Enterprise is a national economic development agency and a non-departmental public body of the Scottish Government, supporting high-growth potential businesses.
What's next for EnteroBiotix?
With the recent influx of capital, EnteroBiotix is set to prioritize the execution of its Phase 2b RISE trial, a critical milestone in its clinical roadmap. The strategic allocation of these funds will likely focus on operational scaling, manufacturing optimization, and the expansion of its research and development capabilities. As the company transitions through this major enterprise-level funding phase, the focus remains on validating the efficacy of its microbiome platform and preparing for potential late-stage clinical milestones. The continued support from both public and private institutional backers provides the necessary runway to navigate the rigorous regulatory environment and maintain its competitive edge in the life sciences sector.
See full EnteroBiotix company page
